with G1 Therapeutics continuing as the surviving corporation and a wholly owned subsidiary of Pharmacosmos Therapeutics Inc., a U.S. subsidiary of Pharmacosmos A/S. In connection with the merger, all shares of G1 Therapeutics common stock (other than (i) shares...
Dividend Stock News REITs Dividend Ideas Dividend Strategy Dividend Quick Picks Editors' Picks Analysis by Sector Energy Communication Services Real Estate Consumer Staples Tech Basic Materials Healthcare Consumer Utilities Financials Industrials Stock Comparison Tools FAANG Stocks Gold ETFs Cash Equivalents Bi...
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the closing of an underwritten public offering of 7,700,000 shares of its common stock at a public offering price of $6.50 per share. RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2022 (GLOBE NEWSWIRE) --G1 Therapeutic...
智通财经APP获悉,6月22日,临床阶段肿瘤公司G1 Therapeutics(GTHX.US)和Genor Biopharma(嘉和生物)宣布了一项独家许可协议引进CDK4/6抑制剂lerociclib在亚太地区(日本除外)的开发和商业化。 根据该协议的条款,G1将获得600万美元的前期现金付款,并有资格获得多达4000万美元的开发和商业里程碑付款。此外,嘉和生物将根...
GTHX is a biotechnology company that is focused on developing innovative therapies for the treatment of cancer.
G1 Therapeutics (NASDAQ: GTHX) Some price data may be temporarily unavailable. G1 Therapeutics Return vs. S&P 1 Year5 Year5 Year AnnualizedSince IPO GTHX +379.87% -79.89% -27.44% -52% S&P +8.41% +88.08% +13.47% +135% G1 Therapeutics Company Info G1 Therapeutics, Inc. engages in...
G1 Therapeutics (NASDAQ:GTHX): Q4 GAAP EPS of -$0.94 beats by $0.02.Cash and equivalents of $269.21M.Press Release